The Case For Non-Viral Circular Single-Stranded HDR Donors

Gene editing is rapidly transforming the treatment landscape for inherited diseases, but enabling precise genetic insertion while preserving long-term cell fitness remains a critical bottleneck. Traditional viral vectors often introduce significant toxicity, manufacturing complexity, and payload limitations that hinder clinical scalability.

A compelling alternative lies in Megabulb DNA (mbDNA™), a proprietary, cell-free, circular single-stranded DNA platform designed to optimize homology-directed repair. By eliminating extraneous bacterial sequences, this minimal structure minimizes cellular stress and immunogenicity, particularly in sensitive primary cells. Independent validation shows that mbDNA-edited stem cells achieve robust engraftment and retain 82% of their population over time, significantly outperforming traditional viral approaches. Compatible with diverse non-viral delivery technologies, this innovation supports safer, scalable, and highly efficient genetic medicines.

Review the complete executive summary to explore the detailed preclinical data and functional validation pathways.